BfArM - Federal Institute for Drugs and Medical Devices

Navigation and service

Dear Doctor Letter (Rote-Hand-Brief) for contraceptives containing dienogest and ethinylestradiol: risk of venous thromboembolism

2018.12.11

Active substance: dienogest, ethinylestradiol

The company Jenapharm GmbH & Co. KG provides information on the risk of venous thromboembolism (VTE) in women using contraceptives containing dienogest and ethinylestradiol compared to women using levonorgestrel and ethinylestradiol combinations, which are associated with a lower risk.

Download DHPC / Information letter , Download_VeroeffentlichtAm_EN PDF, 239KB, File is accessible

Use of cookies

Cookies help us to provide our services. By using our website you agree that we can use cookies. Read more about our Privacy Policy and visit the following link: Privacy Policy (only in German)

OK